Back to results
US 10,328,123 B2Granted
Pulsed introduction of low-dose RANKL as a therapy for atherosclerosis
AssigneeSaint Louis University
InventorsRajeev Aurora, Anna Smith, Angel Baldan
Life of this patent
Estimating the term…
Abstract
Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist suck as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.
Claims7
A method for inhibiting atherosclerosis in a patient the method comprising:
- providing said patient a RANK agonist being of:
- sufficient amount to induce osteoclasts of said patient to produce foxP3+ CD8 T-cells (TcREG);
- and
- insufficient amount to activate enough of said osteoclasts to create new bone loss in said patient;
- repeating said providing according to a fixed schedule so as to provide said RANK agonist to said patient at pulsed intervals, said patient having as a result of said fixed schedule increased bone mass compared to a patient not on said fixed schedule.
2 more elements
Dependencies are inferred from the claim text.